| NCT ID | NCT07713849 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Chicago |
| Condition | Schizoaffective Disorders |
| Study Type | OBSERVATIONAL |
| Enrollment | 75 participants |
| Start Date | 2026-05-06 |
| Primary Completion | 2028-05-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 75 participants in total. It began in 2026-05-06 with a primary completion date of 2028-05-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is testing a new approach to help people with first episode psychosis transition successfully from the hospital to outpatient mental health care. Many patients lose contact with services after they leave the hospital, which can lead to worse outcomes. The investigators have developed a Transition Care Team (TCT) that works with patients while they are in the hospital and continues to support them after discharge. The team provides therapy, case management, and coordination with community programs that offer ongoing care. The main goal of the study is to find out if this new program increases the number of patients who successfully begin outpatient treatment after hospitalization, compared to usual care. The investigators will also look at whether the program improves symptoms, functioning, and overall well-being.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder with psychotic features, major depressive disorder with psychotic features, schizophreniform disorder, or psychosis NOS * The diagnosis of one of the psychotic disorders has a duration of less than two years. * Able to read, speak, and understand English, which will be assessed through observation. * Able and willing to provide written informed consent or assent, in cases where caregivers are considered legal guardians. Dr. Shima, co-I of the study, is a forensic psychiatrist, and particularly adept at judging such ability. Drs. Erickson and Keedy have conducted studies in individuals with psychotic disorders, including FEP and in the context of clinical trials, for years, and are similarly competent to judge whether individuals can provide informed consent. Finally, we will also use an Evaluation to Sign Consent form that documents subjects' verbalized understanding of key aspects of the study. * have an estimated IQ of \> 65, assessed by the Wechsler Test of Adult Reading * Eligible caregivers/proxy informants must be identified by the participant or clinical team as being involved in the participant's discharge planning or follow-up care, be able to provide informed verbal consent, and be able to speak and read English sufficiently to complete study questionnaires. Caregivers may include family members, close supports, or legally authorized representatives. Exclusion Criteria: * Individuals with substance-induced psychosis or psychosis due to a medical condition will not be included in the study. We will use the Structured Clinical Interview for DSM-5 as well as medical records, and if the subject gives permission, caregiver information in this process * Individuals who do not meet criteria for a first episode of psychosis
Contact & Investigator
Molly Erickson, PhD
PRINCIPAL INVESTIGATOR
University of Chicago
Frequently Asked Questions
Who can join the NCT07713849 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 40 Years, studying Schizoaffective Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07713849 currently recruiting?
Yes, NCT07713849 is actively recruiting participants. Contact the research team at keedylab@gmail.com for enrollment information.
Where is the NCT07713849 trial being conducted?
This trial is being conducted at Chicago, United States, Harvey, United States.
Who is sponsoring the NCT07713849 clinical trial?
NCT07713849 is sponsored by University of Chicago. The principal investigator is Molly Erickson, PhD at University of Chicago. The trial plans to enroll 75 participants.